Cytomegalovirus infection

This expanded access program lets doctors in Texas give banked, partially matched virus-specific T cells to children under 18 who have persistent or recurring EBV, CMV, adenovirus, or BK virus infections after an allogeneic stem cell transplant or CAR T therapy. The cells come fr…

This phase 2 trial tests a CMV vaccine (CMV-MVA Triplex) given before a liver transplant to see if it reduces the need for antiviral drugs after surgery. The study enrolls 416 CMV-negative adults awaiting a liver transplant from a CMV-positive donor. Participants receive two vacc…

This study is testing the drug letermovir to prevent cytomegalovirus (CMV) infection in children and teens who have had a kidney transplant and weigh less than 40 kg. About 40 participants will receive the drug to see how it moves through their bodies and if it is safe. The goal …

This study tests whether adding immune cells from a family donor to standard antiviral drugs can help children and young adults clear stubborn adenovirus or cytomegalovirus infections after a stem cell transplant. About 69 participants will be randomly assigned to receive either …

This study tests whether specially grown donor immune cells (viral-specific T-cells) can safely treat viral infections that often occur after a stem cell transplant. These infections can be serious and sometimes don't respond to standard antiviral drugs. The approach aims to boos…

This study tests whether specially grown immune cells from an unrelated donor can safely treat viral infections in people with weakened immune systems, such as after a stem cell transplant. About 750 participants will receive these cells and be monitored for side effects like inf…

This study tests whether giving patients donor-derived immune cells (VSTs) on a regular schedule can prevent dangerous viral infections after a stem cell transplant. 180 participants will be randomly assigned to receive VSTs either on a fixed schedule or only when a virus is dete…

This phase II trial is testing whether an anti-viral drug called valganciclovir (Valcyte) can help treat breast cancer that has spread to the brain. The study includes 28 adults with progressive brain metastases who also have evidence of a common virus called CMV. Participants ta…

This study in Japan tracks 250 organ or stem cell transplant patients whose CMV infection did not improve with standard treatments. Participants take Maribavir tablets as part of their regular care, and doctors monitor side effects and whether the virus clears from the blood for …

This study tests whether the drug letermovir can prevent cytomegalovirus (CMV) from reactivating in people who have received a type of CAR T-cell therapy called axicabtagene ciloleucel. CMV is a common virus that can cause serious illness when the immune system is weakened. The t…

This study tests whether adding the malaria drug artesunate to standard antiviral treatment can better control cytomegalovirus (CMV) infection in people who have received a solid organ transplant (kidney, lung, heart, or liver). About 90 adult participants will receive either a l…

This early-phase trial is testing whether immune cells called R-MVST cells, grown quickly from a healthy donor, can safely fight off stubborn viral infections (EBV, CMV, adenovirus, or BK virus) in children and young adults with weakened immune systems. Participants have not resp…

This phase 2 trial tests whether a blood test that measures CMV-specific immunity (CMV-TCIP) can help doctors decide how long to continue the antiviral drug letermovir after an allogeneic stem cell transplant. Participants receive letermovir for 14 weeks, then the test guides whe…

This study tests a new cell therapy called LB-DTK-MV in children aged 1-25 who have stubborn viral infections (CMV, EBV, or BKV) after a stem cell transplant. The therapy uses specially grown immune cells from a donor to attack the viruses. Participants receive two infusions two …

This study tests a new treatment called LB-DTK-CMV for people with cytomegalovirus (CMV) retinitis that has not responded to standard antiviral medicines. The treatment uses a patient's own immune cells, specially trained to attack CMV, and is given as two infusions. The trial ai…

This early-phase trial tests a treatment called LB-DTK-MV, which uses immune cells from a healthy donor to fight three viruses (CMV, BKV, and EBV) that have become resistant to standard antiviral drugs. The study includes 27 adults who have had a stem cell transplant or certain c…

This study tests whether giving patients special donor immune cells (called CD45RA-depleted DLI) can treat viral infections that persist after a stem cell transplant. The trial involves 30 participants who have not improved with standard antiviral drugs. Researchers will measure …

This study looks at whether stem cell transplant patients can safely stop taking a medicine called letermovir earlier if their immune system shows a strong response to CMV. About 105 participants will be monitored to see if this approach reduces infections and side effects compar…

This early-phase study tests whether specially trained immune cells from healthy donors can safely treat viral infections (EBV, CMV, adenovirus, BK virus) in patients who have had a stem cell transplant or certain CAR-T therapy. These infections can be life-threatening when the i…

This study tests whether the drug letermovir can prevent cytomegalovirus (CMV) from coming back in kidney or kidney/pancreas transplant patients who are at high risk. About 90 adults will take letermovir daily for 84 days and be followed for 6 months. The goal is to see if it red…

This early-stage trial tests whether specially grown immune cells from a donor can safely help transplant patients fight off viral infections that standard treatments can't control. The cells target Epstein-Barr virus, cytomegalovirus, adenovirus, and BK virus. Up to 36 adults wh…

This study tests whether a drug called letermovir is easier to tolerate than the standard treatment for preventing CMV infection in heart and lung transplant recipients. About 80 adults who have had a heart or lung transplant will take either letermovir or the usual drug, and res…

This study tests a drug called maribavir for children and teens who have a CMV infection after a stem cell or organ transplant. About 80 participants will take the drug for 8 weeks and be followed for 12 more weeks. The goal is to find the safest dose and see how well it controls…

This study tests whether the antiviral drug letermovir can prevent cytomegalovirus (CMV) infection in children and teens who have had a stem cell transplant. About 105 participants aged 2 to 17 will receive letermovir and be monitored for 14 weeks. The goal is to see if the drug …

This early study tests whether immune cells from a donor can safely fight cytomegalovirus (CMV) or adenovirus (AdV) infections in people who have had a stem cell or solid organ transplant. About 20 participants will receive these virus-specific T-cells intravenously. The main goa…

This study tests whether a web app that customizes the dose of the antiviral drug ganciclovir can clear cytomegalovirus (CMV) faster in 232 children with weakened immune systems. Participants are recruited from seven hospitals in Australia and New Zealand. The goal is to see if p…

This study looks at the best length of treatment with the drug maribavir for a hard-to-treat CMV infection that can happen after a stem cell transplant. About 218 adults who have already had a transplant and have this infection will be randomly assigned to different treatment dur…

This study tests whether the drug letermovir can stop cytomegalovirus (CMV) in unborn babies better than the current treatment valaciclovir. Pregnant women with a CMV-infected fetus will take one of the two drugs daily until delivery. The goal is to see if letermovir leads to a n…

This study tests whether adding special immune cells from the mother to standard antiviral medicine can safely and more effectively treat moderate to severe CMV infection in newborns. Babies up to 21 days old with confirmed CMV disease may join. All receive antiviral drugs, and s…

This study looks at whether monitoring the immune response to the cytomegalovirus (CMV) can help prevent CMV disease in people who receive a lung transplant. About 100 adult lung transplant patients who have had CMV in the past will be followed. The goal is to see if tracking CMV…

This study tests a drug called maribavir in Chinese adults who had a stem cell or organ transplant and have a CMV infection that did not get better with standard treatments. The main goal is to see if maribavir is safe and well-tolerated. Researchers will also check if the drug c…

This study tests whether specially selected immune cells from a donor can safely treat cytomegalovirus (CMV) and adenovirus (ADV) infections in children who have had a stem cell transplant. About 42 participants will receive these virus-fighting cells and be monitored for viral l…

This study compares two ways to prevent cytomegalovirus (CMV) infection in kidney transplant patients who already carry the virus. One approach gives antiviral drugs to everyone for 3 months, while the other uses immune system tests to decide who needs treatment. The goal is to s…

This study tests whether adding letermovir to standard antiviral treatment helps clear cytomegalovirus (CMV) infection faster in people who have received a lung transplant. About 40 participants will receive either letermovir or a placebo alongside their usual medication for 21 d…

This study tests whether adding letermovir to the standard drug valganciclovir works better than valganciclovir alone for treating CMV infections in kidney transplant recipients. About 80 adults who have a kidney transplant and a CMV infection will take part. The goal is to see i…

This study tests whether giving CytoGam® (CMV immunoglobulin) after standard antiviral treatment can prevent late CMV infection in high-risk kidney or liver transplant recipients. About 80 participants who are CMV-negative but receive an organ from a CMV-positive donor will be en…

This study tests if valacyclovir works as well as valganciclovir to prevent CMV and EBV infections in kidney transplant patients. Valganciclovir can cause bone marrow suppression, a serious side effect. The study will enroll 80 kidney transplant recipients and monitor them for ne…

This study tests whether the drug maribavir can safely control cytomegalovirus (CMV) infections in people with multiple myeloma or lymphoma who are receiving bispecific antibody therapy. About 20 adults will take maribavir, and researchers will measure how well it lowers CMV leve…

This study is testing whether the antiviral drug letermovir can prevent a common and serious viral infection called CMV in people with relapsed/refractory multiple myeloma who are receiving the immunotherapy elranatamab. The trial will enroll 40 adults who are CMV-positive. Resea…

This study follows 168 adults in South Korea who have had a transplant and developed a CMV infection that didn't respond to other treatments. They will take LIVTENCITY (Maribavir) as part of routine care, and researchers will track side effects and how well the drug clears the vi…

This study is testing whether a drug called Cytogam (CMVIG) can prevent cytomegalovirus (CMV) infection in kidney transplant patients who are switching to a new immunosuppressant. The researchers will measure antibody levels in 30 adult patients over 8 weeks to see how the drug w…

This study tests an experimental therapy that uses special immune cells (T-cells) from a donor to fight cytomegalovirus (CMV) infection in people who have had a stem cell transplant. The therapy aims to boost the patient's immune system to clear the infection. About 20 participan…

This study tests a vaccine called CMV-MVA Triplex in 80 children who have had a stem cell transplant and are at risk for CMV infection. The goal is to find the best dose and see if it safely prevents CMV reactivation. Participants receive the vaccine and are monitored for side ef…

This study tests whether a newer drug, letermovir, is safer and more effective than the standard valganciclovir for preventing CMV infection in heart transplant recipients. About 150 moderate- to high-risk adults will be enrolled. The main focus is on reducing side effects like l…

This study looks at 200 adults with inflammatory bowel disease (IBD) who are hospitalized due to worsening symptoms. Researchers want to see if testing blood or stool for CMV (a common virus) is as accurate as the standard method of testing a tissue sample from the colon. The goa…

This study tests a decision-support tool called MyCMV that helps doctors interpret blood test results for cytomegalovirus (CMV) infection during pregnancy. CMV is a common virus that can cause hearing loss and developmental problems in babies if the mother catches it for the firs…

This early-phase trial tests a vaccine (CMV-MVA Triplex) given to both stem cell donors and recipients to boost immunity against cytomegalovirus (CMV) and prevent active infection after a half-matched stem cell transplant. About 46 people with various blood cancers will take part…

This study tests a personalized approach to stopping the drug Letermovir, which prevents a common virus called CMV after a stem cell transplant. Instead of giving the drug for a fixed 100 days, doctors will use a blood test to see when a patient's own immune system has recovered …

This study tests two different approaches to prevent cytomegalovirus (CMV) disease in adults who have received a kidney from a CMV-positive donor but are themselves CMV-negative. One group will take daily antiviral medicine for 200 days after transplant, while the other group wil…

This phase 2 trial tests a vaccine called CMV-MVA Triplex, given to stem cell donors before they donate. The goal is to boost the donor's immunity against cytomegalovirus (CMV), which can then be passed to the transplant patient. Researchers hope this will prevent CMV infection i…

This study looks at whether giving letermovir for a longer time (up to 28 weeks) can prevent cytomegalovirus (CMV) infection in Chinese adults who have a high risk of reactivation after a stem cell transplant. Participants must be at least 18, have had a stem cell transplant, and…

This study compares a new drug called leymovir to the standard drug valganciclovir for preventing cytomegalovirus (CMV) infection in 290 Chinese kidney transplant recipients. Leymovir targets a different part of the virus, which may reduce side effects like bone marrow suppressio…

This study looks at people who have had unusually severe or long-lasting viral infections, like serious cases of herpes, HPV, or the flu. Researchers want to find out if these people have hidden immune system or genetic problems that make them more vulnerable. Up to 600 participa…

This study looks at how well the immune system recovers its ability to fight cytomegalovirus (CMV) in adults who have had a stem cell transplant. Researchers will measure special immune cells called CMV-specific T cells at several points during standard anti-CMV treatment. The go…

This study is looking at 100 adult patients who have had an organ or stem cell transplant and later developed a CMV infection that is resistant or hard to treat with standard antiviral drugs. Researchers want to find out how common this problem is and what factors make it more li…

This study analyzes dried blood spots from 630 newborns to find protein and RNA markers that could predict which babies with congenital CMV will develop hearing loss or other problems. Researchers will compare samples from infected babies who had complications, those who did not,…

This observational study follows 350 adults with blood cancers like lymphoma or multiple myeloma who are being treated with bispecific antibodies. Researchers will track how often infections occur, how severe they are, and what factors raise infection risk. The goal is to better …

This study reviews medical records of 230 children in Italy who received a stem cell transplant between 2018 and 2020. Researchers want to understand how common and costly cytomegalovirus (CMV) reactivation is in these young patients. The goal is to give doctors and health offici…

This study is looking for immune system markers that might predict whether a pregnant woman with a first-time HCMV infection will pass the virus to her unborn baby. Researchers will study blood samples from 90 pregnant women and their newborns to see which immune responses are li…

This study follows 40 lung transplant patients who are at high risk for CMV infection because the donor had CMV but the recipient did not. Researchers want to learn how often the virus breaks through during standard antiviral treatment with valganciclovir. They will also track si…

This study will test 10,000 people in Cambodia for 57 different infectious diseases, including dengue, flu, and malaria. Researchers want to understand how these diseases spread and who is at risk. The goal is to give local health authorities the information they need to create b…

This study collects information from 450 newborns who fail their initial hearing screening. Doctors will test them for congenital CMV, a common infection that can cause hearing loss and other problems. The goal is to see how often CMV is found and to improve follow-up care for af…

This study reviews medical records of 10 adult transplant patients who have a hard-to-treat CMV infection along with severe kidney disease or kidney failure. Researchers want to see how safe the drug maribavir is for these patients. No new treatments or procedures are given; the …